Elmiron Settlements
Multidistrict litigation against Elmiron could likely resolve soon, according to legal experts familiar with the matter. Lawsuits name injuries such as retinal pigmentary changes. These changes can resemble inherited retinal disorders such as macular degeneration, also known as maculopathy.
Drugwatch.com content is legally reviewed for accuracy and quality.
Examples of trusted legal reviewers include qualified mass torts lawyers and certified paralegals.
Drugwatch.com writers gather lawsuit information by studying court records, watching lawsuit proceedings and speaking with experienced attorneys.
Drugwatch.com has been empowering patients for more than a decade
Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008. We’ve also connected thousands of people injured by drugs and medical devices with top-ranked national law firms to take action against negligent corporations.
Our team includes experienced medical writers, award-winning journalists, researchers and certified medical and legal experts. Drugwatch.com is HONCode (Health On the Net Foundation) certified. This means the high-quality information we provide comes from credible sources, such as peer-reviewed medical journals and expert interviews.
The information on Drugwatch.com has been medically and legally reviewed by more than 30 expert contributors, including doctors, pharmacists, lawyers, patient advocates and other health care professionals. Our writers are members of professional associations, including American Medical Writers Association, American Bar Association, The Alliance of Professional Health Advocates and International Society for Medical Publication Professionals.
About Drugwatch.com
- Assisting patients and their families since 2008.
- Helped more than 12,000 people find legal help.
- A+ rating from the Better Business Bureau.
- 5-star reviewed medical and legal information site.
Testimonials
"Drugwatch opened my eyes to the realities of big pharmacy. Having a family member with major depression and anxiety, I was looking for information on her medications. I found information that was very helpful, that her psychiatrist never told her."
Latest Elmiron Settlement Status
As of November 2024, there were 1,438 pending cases in multidistrict litigation against Elmiron manufacturer Janssen Scientific Affairs, though experts suggest Bellwether trials may currently be in settlement discussions. No formal settlement has been announced for MDL 2973 yet, however.
Legal experts predict the MDL will result in a settlement. Structured payouts will likely be based on different injury tiers, with each plaintiff receiving set compensation according to their sustained damages.
- November 2023: The latest court docket filings indicate settlements are in progress.
- August 2023: U.S. District Judge Brian R. Martinotti in New Jersey approved an order to establish common fee and expense funds for the plaintiffs' attorneys in the MDL.
- April 2023: Both parties in what was to be the first bellwether case filed a joint motion asking all motions to be withdrawn, indicating lawyers are in the process of negotiation settlement. Janssen, a subsidiary of Johnson & Johnson, disclosed it spent $6.9 million in total litigation costs for all of its subsidiaries in the first quarter of 2023.
- March 2023: The first bellwether trial in the MDL began on March 27.
People who took Elmiron to treat their chronic bladder condition, interstitial cystitis, have filed Elmiron lawsuits against manufacturer Janssen Scientific Affairs. Plaintiffs allege the drug caused them to develop vision-threatening eye conditions, including pigmentary or retinal maculopathy and macular degeneration.
If you think you may have a lawsuit against Elmiron, there is still time to file. Contact an experienced medical products litigation lawyer as soon as possible.
How Are Settlement Amounts Determined?
A particular outcome in settlement negotiations isn’t guaranteed. The extent of vision loss the plaintiff sustained will likely be the primary factor in determining Elmiron lawsuit settlement amounts. Plaintiffs may seek compensation for both economic and non-economic damages.
- Future Medical Expenses
- Loss of Consortium
- Loss of Enjoyment of Life
- Lost Income
- Medical Bills
- Mental Health Effects
- Reduced Earning Capacity
- Pain
State laws and regulations may also influence settlement amounts. The availability and strength of the evidence and the expected outcome of bellwether trials also play significant roles.
How Long Will an Elmiron Settlement Take?
Once the multidistrict litigation is resolved, the settlement process should speed up. Lawyers with knowledge of the case say settlements could likely be reached in 2023. Some settlements can take years, but the Elmiron lawsuits will probably get resolved within months, according to legal experts.
Factors impacting settlement timing include the resolution of the bellwether cases and whether your claim is part of the associated MDL. There are also individual cases outside of the MDL in state courts.
Who Qualifies for an Elmiron Settlement?
You may be eligible to file an Elmiron claim if you used Elmiron and experienced vision loss as a result. An experienced attorney can help you document your medical diagnosis and the period of your Elmiron use and assess the strength of your case.
If you’re experiencing vision damage and haven’t yet been diagnosed or are seeking a second opinion, be sure to discuss your history of taking Elmiron with the doctor. Without full knowledge of the medication you’ve taken, patients can sometimes be misdiagnosed.
Calling this number connects you with a Drugwatch.com representative. We will direct you to one of our trusted legal partners for a free case review.
Drugwatch.com's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.